.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The SENSCIS trial evaluated nintedanib in adults with systemic sclerosis-associated interstitial lung disease, a population in whom progressive fibrosis can cause substantial morbidity. In this randomized placebo-controlled study, nintedanib reduced the annual rate of decline in forced vital capacity compared with placebo, supporting an antifibrotic treatment strategy in this form of connective-tissue-disease ILD. Diarrhea was the most frequent adverse event, making tolerability and patient counselling important parts of treatment planning. The study does not mean that every patient with systemic sclerosis should automatically receive nintedanib; rather, it adds evidence for a disease-modifying option when clinically meaningful ILD is present and progression is a concern. This aligns closely with the NAPCON ILD session's focus on connective-tissue-disease-associated ILD and antifibrotics beyond classic IPF. The clinically useful lesson is to identify ILD early, quantify disease burden and follow trajectory with symptoms, lung function and imaging. Treatment decisions then become part of an ongoing reassessment process rather than a one-time choice. SENSCIS is also a useful reference when discussing how the antifibrotic evidence base has expanded from IPF into broader fibrosing lung disease.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The SENSCIS trial evaluated nintedanib in adults with systemic sclerosis-associated interstitial lung disease, a population in whom progressive fibrosis can cause substantial morbidity. In this randomized placebo-controlled study, nintedanib reduced the annual rate of decline in forced vital capacity compared with placebo, supporting an antifibrotic treatment strategy in this form of connective-tissue-disease ILD. Diarrhea was the most frequent adverse event, making tolerability and patient counselling important parts of treatment planning. The study does not mean that every patient with systemic sclerosis should automatically receive nintedanib; rather, it adds evidence for a disease-modifying option when clinically meaningful ILD is present and progression is a concern. This aligns closely with the NAPCON ILD session's focus on connective-tissue-disease-associated ILD and antifibrotics beyond classic IPF. The clinically useful lesson is to identify ILD early, quantify disease burden and follow trajectory with symptoms, lung function and imaging. Treatment decisions then become part of an ongoing reassessment process rather than a one-time choice. SENSCIS is also a useful reference when discussing how the antifibrotic evidence base has expanded from IPF into broader fibrosing lung disease.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
2 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
3 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
3 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
4 days back
